SPRX002 is named as an intervention in 2 current clinical trials in our USA, UK, Germany, France, Spain, Italy, Netherlands, Belgium, Switzerland, Austria, Canada, Japan, Australia and Israel registers. None are recruiting at the moment. The most common phase is Observational. The sponsor with the most trials is Kite, A Gilead Company (1). The most-studied condition is Solid and Hematological Malignancies.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Long-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite Studies
NCT05041309 · ClinicalTrials.gov ↗ · Solid and Hematological Malignancies, Autoimmune Diseases
|
Observational | By invitation | Kite, A Gilead Company | UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Switzerland, Austria, Canada, Japan, Australia, Israel |
|
Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS
NCT05457010 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia, Myelodysplastic Syndromes
|
Phase 1 | Active, closed | Arcellx, Inc | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Kite, A Gilead Company | 1 |
| Arcellx, Inc | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our USA, UK, Germany, France, Spain, Italy, Netherlands, Belgium, Switzerland, Austria, Canada, Japan, Australia and Israel registers name SPRX002 as a drug or biological intervention, as of the registry sync on 29 September 2026. Completed and withdrawn studies are not counted.
Not at the moment. None of the 2 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
Kite, A Gilead Company (1) and Arcellx, Inc (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how SPRX002 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how SPRX002 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists SPRX002 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 29 Sep 2026.